NUVALENT INC - CLASS A (NUVL)

However, it will result in low-single-digit percentage dilution to core earnings per share until 2028 and will contribute to the metric only from 2029. The deal is expected to close in the third quarter this year. On Stocktwits, retail sentiment about NUVL remained ‘bullish,’ while it turned ...

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

GSK has agreed to ​buy U.S.-listed cancer drug developer Nuvalent for $10.6 billion in its largest deal in more than a decade, marking a strategic shift under new CEO ‌Luke Miels as the British company steps up its focus on oncology.

Nuvalent Inc. stocks have been trading up by 39.22 percent following highly positive sentiment around its latest oncology pipeline developments. Key Takeaways For NUVL Traders Financial Times says GSK is in advanced talks to buy Nuvalent in a $9B–$10B deal, with terms possibly agreed this ...

US stocks higher, Dow Jones index up 300 points on strong earnings and sales guidance from J.M. Smucker Co (SJM). Other top gainers include Nuvalent (NUVL), FuelCell Energy (FCEL), and Aduro Clean Technologies (ADUR).